98%
921
2 minutes
20
Background: Stage T1a renal cell carcinoma (RCC) (tumors <4 cm) is usually curable. Nephron-sparing partial nephrectomy (PN) has replaced radical nephrectomy (RN) as the standard of care for these tumors. Radical nephrectomy remains the first alternative treatment option, whereas percutaneous ablation (PA), a newer, nonsurgical treatment, is recommended less strongly because of the relative paucity of comparative PA data.
Objective: To compare PA, PN, and RN outcomes.
Design: Observational cohort analysis using inverse probability of treatment-weighted propensity scores.
Setting: Population-based SEER (Surveillance, Epidemiology, and End Results) cancer registry data linked to Medicare claims.
Patients: Persons aged 66 years or older who received treatment for T1a RCC between 2006 and 2011.
Interventions: PA versus PN and RN.
Measurements: RCC-specific and overall survival, 30- and 365-day postintervention complications.
Results: 4310 patients were followed for a median of 52 months for overall survival and 42 months for RCC-specific survival. After PA versus PN, the 5-year RCC-specific survival rate was 95% (95% CI, 93% to 98%) versus 98% (CI, 96% to 99%); after PA versus RN, 96% (CI, 94% to 98%) versus 95% (CI, 93% to 96%). After PA versus PN, the 5-year overall survival rate was 77% (CI, 74% to 81%) versus 86% (CI, 84% to 88%); after PA versus RN, 74% (CI, 71% to 78%) versus 75% (CI, 73% to 77%). Cumulative rates of renal insufficiency 31 to 365 days after PA, PN, and RN were 11% (CI, 8% to 14%), 9% (CI, 8% to 10%), and 18% (CI, 17% to 20%), respectively. Rates of nonurologic complications within 30 days after PA, PN, and RN were 6% (CI, 4% to 9%), 29% (CI, 27% to 30%), and 30% (CI, 28% to 32%), respectively. Ten percent of patients in the PN group had intraoperative conversion to RN. Seven percent of patients in the PA group received additional PA within 1 year of treatment.
Limitations: Analysis of observational data may have been affected by residual confounding by provider or from selection bias toward younger, healthier patients in the PN group. Findings from this older study population are probably less applicable to younger patients. Use of SEER-Medicare linked files prevented analysis of patients who received treatment after 2011, possibly reducing generalizability to the newest PA, PN, and RN techniques.
Conclusion: For well-selected older adults with T1a RCC, PA may result in oncologic outcomes similar to those of RN, but with less long-term renal insufficiency and markedly fewer periprocedural complications. Compared with PN, PA may be associated with slightly shorter RCC-specific survival but fewer periprocedural complications.
Primary Funding Source: Association of University Radiologists GE Radiology Research Academic Fellowship and Society of Interventional Radiology Foundation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8243237 | PMC |
http://dx.doi.org/10.7326/M17-0585 | DOI Listing |
Urol Oncol
September 2025
Department of Urology, UC San Diego School of Medicine, La Jolla, USA; Department of Urology, Rush Universtiy Medical Center, Chicago, USA. Electronic address:
Objective: Outcomes of stage 1 renal cell carcinoma (RCC) are heterogeneous and vary widely. We sought to investigate whether tripartite reclassification of current binary T1 RCC would lead to more rational consolidation of similar outcomes that may improve predictive ability.
Methods: We performed a retrospective multicenter analysis of patients undergoing radical (RN) or partial nephrectomy (PN) for clinical T1N0M0 RCC.
J Robot Surg
September 2025
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The aim of our study is to compare and assess the correlation of preoperative factors, intraoperative events and post-operative outcomes of robot assisted transperitoneal (RATP) and robot assisted retroperitoneal (RARP) partial nephrectomy (PN) in T1 renal cancer. Data from 2609 patients during the period of 10 years who underwent either RATP or RARP partial nephrectomies was retrospectively analyzed. We compared preoperative factors (age, BMI, tumour size/stage, PADUA score, preoperative eGFR, history of previous abdominal and ipsilateral surgery), intraoperative events: operative time (OT), warm ischemia time (WIT), estimated blood loss (EBL), and post-operative outcomes: complications, eGFR, positive surgical margins (PSM), and death due to disease (DOD) or due to other causes (DOC) and survival rates.
View Article and Find Full Text PDFKidney Cancer J
September 2024
University of Virginia School of Medicine, Department of Public Health Sciences, 200 Jeanette Lancaster Way, Charlottesville, VA 22903.
Background: Microwave ablation (MWA) is an emerging treatment modality for clinical T1a (cT1a) small renal masses (SRM) with studies showing it has comparable oncological outcomes to partial nephrectomy (PN). However, more research is needed to the impact of each treatment on kidney function decline.
Objective: To compare the progression of kidney function decline in patients with cT1a SRM treated with MWA or PN.
Clin Genitourin Cancer
August 2025
Department of Urology, UC San Diego School of Medicine, La Jolla, CA. Electronic address:
Introduction: Lymphovascular invasion (LVI) is a recognized adverse pathological feature in renal cell carcinoma (RCC). However, its impact on staging and prognosis remains poorly defined, especially across T-stage subcategories.
Patients And Methods: We analyzed surgically treated RCC patients from the National Cancer Database (NCDB), including clear cell, papillary and chromophobe RCCs.
BMC Urol
July 2025
Department of Radiology, Medicana Ataköy Hospital, Istanbul, Turkey.
Purpose: This study aimed to evaluate and compare the clinical efficacy and renal function outcomes of microwave ablation (MWA) alone versus MWA combined with transarterial chemoembolization (MWA + TACE) in patients with T1a renal cell carcinoma (RCC), with a focus on tumor complexity as defined by RENAL nephrometry scores.
Materials And Methods: In this retrospective single-center cohort study, 24 patients with T1a RCC were treated with either MWA ( = 14) or MWA + TACE ( = 10) between November 2020 and December 2024. Tumor response, residual enhancement rates, and renal function parameters were analyzed.